Article Text

Download PDFPDF


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Our article Nanomedicines – what are they? (DTB 2011; 49: 58–60) reported that medicines containing nanoparticles available in the EU include oral suspensions of aprepitant (Emend) and sirolimus (Rapamune). The source of this information was a European Medicines Agency document, stating that medicinal products containing nanoparticles in the form of “suspensions (i.e. Rapamune, Emend) have already been granted Marketing Authorisations within the Community under the existing regulatory framework”.1 We have since learned that there are no oral suspension formulations of these drugs marketed in the EU.


Linked Articles

  • Articles
    BMJ Publishing Group Ltd